InvestorNewsBreaks – Pressure BioSciences Inc. (PBIO) Enters New Contract Expected to Generate Significant 2023 Revenue, Drive Accelerated Future Growth

Pressure BioSciences (OTCQB: PBIO) (“PBI”) is a leader in the development and sale of broadly enabling, pressure-based instruments, consumables and specialty testing services to the worldwide nutraceuticals, biotherapeutics and other industries. The company today announced its entry into an agreement with North Star Holdings (“NSH”) on the financial partnership for the development, production, distribution and commercial roll-out of NSH’s novel, effectively water-soluble, nanoemulsified CBD spray for topical use. In addition, PBI will partner with the NSH team on the development and distribution of additional nano-CBD containing products that the highly successful Colorado cannabis operator has already suggested. “John’s years of experience in the cannabis space, his highly successful and vertically-integrated state-wide enterprise, and his company’s rapid growth over the past seven years to nearly $20 million in annual revenue is very impressive,” said Richard T. Schumacher, president and CEO of PBI, speaking of NSH and its president and CEO John Kaweske. “John has already delivered highly valuable perspectives and strategies that we believe will help NSH get their new nano-CBD topical product to market faster and more efficiently than could have happened had we partnered with anyone else. This is a tremendous opportunity for both NSH and PBI, one that we believe will generate several million dollars in annual revenues for PBI in 2023, with exciting, accelerating growth into the future.”

To view the full press release, visit https://ibn.fm/CxkQd

About Pressure BioSciences Inc.

Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). The company’s primary focus is the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) recently acquired, patented technology from BaroFold Inc. (the BaroFold technology) to allow entry into the bio-pharma contract services sector, and (2) recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information about the company, visit www.PressureBioSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.